Video: Interferon-free regimen effective for HCV at 12-week treatment duration

Provided by Healio

October 17, 2013

SAN DIEGO — Kris Kowdley, MD, director of the Liver Center of Excellence at the Digestive Disease Institute of Virginia Mason Medical Center in Seattle, discusses the results of the AVIATOR trial, which he presented at the American College of Gastroenterology Annual Scientific Meeting.

In a phase 2b study, researchers administered an all-oral regimen of two or three direct-acting antivirals, including protease inhibitor ABT-450 with ritonavir, NS5A inhibitor ABT-267 and non-nucleoside NS5B inhibitor ABT-333, with or without ribavirin, to a cohort of patients with HCV genotype 1 for 8, 12 or 24 weeks.

All treatment arms had sustained virologic response rates of over 80% 24 weeks after treatment completion. Among 247 patients who received all three DAAs with ribavirin for 12 or 24 weeks, SVR24 occurred at a similar rate (more than 90%) in both treatment-naïve and prior null-responders to interferon-based therapy.

SVR24 rates were also high in this population regardless of age, sex, race, BMI, IL28B or HCV genotype, baseline HCV RNA levels and fibrosis severity. Incidences of breakthrough and relapse were rare, and adverse events occurred at similar rates in the 12- and 24-week groups.

Disclosure: The researchers report numerous financial disclosures.

For more information:

Kowdley K. #39: Safety and Efficacy of Interferon-free Regimens of ABT-450/r, ABT-267, ABT-333 +/- Ribavirin in Patients with Chronic HCV GTI Infection: Results from the Aviator Study. Presented at: The American College of Gastroenterology Annual Scientific Meeting; Oct. 11-16, San Diego.

Source